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1. Introduction
  In cirrhotic portal hypertension splenomegaly patients with 
hypersplenism, peripheral blood cell counts demonstrats 
different levels of decrease in the overwhelming majority 
of patients because of strengthened splenic pathological 
function, but how to quantify the degree and range of the 
blood cell decrease is still a challenge[1]. Between January, 
1991 and June, 2010, 322 cirrhotic portal hypertension 
patients with decreased peripheral blood cell count were 
studied. The summary report is as follows: 
     
2. Materials and methods
2.1. Clinical data and methods
  Among selected 322 patients, 199 were male and 123 
female, and the ratio of male to female was 1.6:1. They 
were aged from 5-66 years old, and the average was 
43 years old. Among them were 312 cases (96.9%) of 
posthepatitic cirrhosis, 6 cases of biliary cirrhosis, 2 cases 
of schistosomial cirrhosis, and 2 other types of cirrhosis. 
Objective: To explore peripheral blood cell variations in hepatic cirrhosis portal hypertension 
patients with hypersplenism. Methods: Clinical data of 322 hypersplenism patients with 
decreased peripheral blood cells, admitted with cirrhotic portal hypertension, was retrospectively 
studied over the last 17 years. Results: In 64% (206/322) of patients, more than 2 kinds of blood 
cell were decreased, including 89 cases of pancytopenia (43.2%), 52 cases of WBC + PLT  decrease 
(25.2%), 29 cases of RBC + PLT decrease (14.1%), and 36 cases of WBC + RBC decrease (17.5%); 
in 36% (116/322) of patients, single type blood cell decrease occurred, including 31 cases of PLT 
decrease (26.7%), 29 cases of WBC decrease (25%) and 56 cases of RBC decrease (48.3%). Of 227 
routine bone marrow examinations, bone marrow hyperplasia was observed in 118 cases (52.0%), 
the remainder showed no hyperplasia. For the distinct scope and extent of peripheralblood cell 
decreases, preoperative blood component transfusions were carried out, then treated by surgery, 
after whole group splenectomy, the peripheral blood cell count was significantly higher (P<0.05). 
Conclusions: Of portal hypertensive patients with splenomegaly and hypersplenism, 64% have 
simultaneous decrease in various blood cells, 36% have decrease in single type blood cells, 52% 
of patients have bone marrow hyperplasia. A splenectomy can significantly increase the reduction 
of peripheral blood cells.
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All the patients suffered universal splenomegaly, upper 
gastrointestinal radiography or endoscopy examinations 
showed moderate and severe varicous veins in the lower 
esophagus and fundus gastricus (stomach fundus), 65 
patients (20.2%) were hospitalized due to gastrointestinal 
hemorrhaging, 219 patients (68.0%) had a history of 
hemorrhaging. The average size of the spleen as measured 
by B ultrasound examination or CT scan was 224 mm暳159 
mm暳95 mm. 
  
2.2. Statistical analysis
  The Blood cell decrease scope was analyzed by analysis of 
variance (ANOVA), SPSS software package processing, data 
with F value indicated, the uneven use of variance Kruskal-
Wallis test, P<0.05 was considered as statistically significant 
difference.
3. Results
  Peripheral blood white blood cell (WBC) count was <4.0暳
10
9/L, red blood cell (RBC) count <4.0暳10
12/L and platelet 
(PLT) count <110暳10
9/L, indicating peripheral blood cell 
decrease. In this paper, simultaneous decreases in WBC, 
RBC and PLT occurred in 89 cases (27.6), WBC + PLT 
decreases in 52 cases (16.1%), RBC + PLT decreases in 29 
cases (9.0%), and WBC + RBC decreases in 36 cases (11.2%); 
single type PLT decreases occurred in 31 cases (9.6%), single 
type WBC decreases in 29 cases (9.0%), and single type RBC 
decreases in 56 cases (17.4%) (Table 1). 
Table 1
 Peripheral blood cell decrease in 322 case (mean暲SEM).
Group               n WBC(暳10
9/L) RBC(暳10
12/L) PLT(暳10
9/L)
Pancytopenia 89 2.35暲0.76 2.99暲0.24 58.6暲19.8 
WBC+PLT 52 2.76暲0.71* - 56.9暲21.2 
RBC+PLT 29 - 2.83暲0.20* 67.2暲21.3
WBC+RBC 36 2.85暲0.76* 3.11暲0.30 -
PLT 31 - - 66.2暲23.3
WBC 29 2.98暲0.65* - -
RBC 56 - 2.71暲0.50* -
*P<0.05 vs. Pancytopenia group. The difference in PLT was 
insignificant (P>0.05, F=1.61).
  Of 227 bone marrow aspiration examinations, 118 cases 
had bone marrow hyperplasia (52.0%). After complete blood 
transfusions to replenish the shortage of tangible blood 
components, all the patients underwent splenectomy, 
and simultaneously 252 cases had cardiac peripheral 
vascular surgery, 56 cases had splenorenal shunt, 9 cases 
had mesocaval shunt, and 5 cases had portacaval shunt. 
Measurement via the right gastroepiploic vein showed the 
free portal venous pressure was 26 cm H2O-54 cm H2O, and 
the average was 34 cm H2O. The average spleen size was 
236 mm暳169 mm暳96 mm. In postoperative pathological 
examinations, splenic blood stasis, lots of phagocyte and 
severe fibroplasia was observed. Postoperative follow-up 
was conducted in 226 patients, for 3-96 months, and 63 
months on average. 
  The comparison of pre-operative and post-operative 
peripheral blood cell count is shown in Table 2. 
Table 2
Pre-operative and post-operative hemocyte in 226 case (mean暲SEM).
Item Pre-operation Post-operation t value P value
WBC(暳10
9/L)   2.57暲0.71   7.43暲3.03 8.59 <0.01
RBC(暳10
12/L)   2.98暲0.54   3.88暲0.63 5.33 <0.01
PLT(暳10
9/L) 51.75暲21.68 243.6暲128.49 5.67 <0.01
4. Discussion
  In China, most portal hypertension splenomegaly is caused 
by posthepatitic cirrhosis. Splenomegaly and decreases 
in single or multiple type blood cells in peripheral blood 
are the main clinical manifestation of hypersplenism 
and an important foundation of hypersplenism diagnosis. 
Hypersplenism was proposed by Cretsel as early as 1866, 
described in detail by Banti in 1883 and consequently named 
as Banti syndrome, and definitively named by Chauffard in 
1907[2]. In 1955, Doan[3] conducted further research and the 
prerequisites for hypersplenism: splenomegaly; decrease 
in single or multiple type blood cell components; normal 
bone marrow or bone marrow hyperplasia; the pathological 
changes in blood constituent disappears after splenectomy.
The above 4 prerequisites are for general hypersplenism 
diagnosis, but to assess whether cirrhotic patients with portal 
hypertension have hypersplenism due to splenomegaly 
itself even as a condition of portal hypertension, is mainly 
diagnosed based on the changes in peripheral blood cell. In 
this group, 64% manifested decreases in multiple type blood 
cells and 36% manifested decreases in single type blood 
cells. 
  There are currently 5 main theories for the pathogenesis 
of multiple type blood cell decreases: (1) Intrasplenic stasis 
theory[4] Following splenomegaly, splenic blood volume is 
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increased, large quantities of WBC, RBC and PLT clog the 
spleen, the ratio of clogged blood cells in the spleen is 5.5-
20 times larger than that of a normal spleen, which leads 
to decrease in peripheral blood cells; (2) Phagocytic theory 
says the spleen contains a large amount of monocyte and 
macrophage, in pathological conditions, the abilities of 
monocyte and macrophage to swallow and destroy blood cells 
are significantly strengthened, especially the destruction of 
red blood cells[5]. In recent years, related researches were 
conducted by RBC life-sensitive marker EC, and found 
EC level in patients with splenomegaly and postnecrotic 
cirrhosis is significantly higher than those in patients with 
normal spleen and hepatic cirrhosis and in patients of 
normal control group (P < 0.05), and the difference between 
the later two groups was insignificant[4], which illustrates that 
splenomegaly accelerates RBC destruction; (3) Bone marrow 
suppression theory says alcohol and hepatitis viruses have 
direct inhibitory effect on bone marrow precursor cells, and 
can affect blood cell generation[6,7]. Furthermore, the spleen 
may produce redundant “splenic hormones” inhibiting the 
blood-producing function of bone marrow and accelerating 
destruction of generated blood cells and obstructing their 
entrance into blood circulation[8]; (4) Autoimmune theory 
says the spleen is a large lymphatic organ, where antibodies 
are produced. Antigens untreated by the liver enter the 
periphery of splenic lymphoid follicles (splenic nodule), 
and after antigen stimulation, causes prolymphocyte and 
plasmocyte reactions, producing antibodies[4], which results 
in the destruction of its own blood cells and consequently 
decreasing peripheral blood cells; (5) Blood loss theory 
shows acute blood loss can decrease complete blood cell 
count. Usually, these theories coexist, and rarely do only one 
theory comes into play.  
  The pathogenesis of decreases in single type blood cells is 
currently not clear. The further studies on haematopoietic 
physiology in recent years, especially the discovery of 
blood cell growth factor, have opened another door to 
the pathophysiological disorder of blood cells in hepatic 
diseases. 
  There are various factors to red blood cell decreases, 
but all are closely related to erythropoietin (EPO), which 
is produced by kidney and liver. Renal failure and EPO 
level maladjustments are important factors, the EPO value 
in cirrhosis patients is insufficient and insensitive to the 
anemia degree[9], and in renal failure patients, various 
factors can cause EPO resistance[10]. 
  Similarly, there are more than one single factor at play in 
the decrease of white blood cells. It has been proven by in 
vitro culture and testing that the apoptosis of neutrophil and 
polymorphonuclear leukocyte in cirrhosis patients is more 
rapid than that in normal control patients, which can lead to 
a decrease in the white blood cell count[11]. 
  Research in recent years has demonstrated that 
thrombocytopenia is related to thrombopoietin (TPO), while 
in cirrhosis patients, TPO reduces[12], the production and 
destruction of TPO is unbalanced[13]. TPO is seemingly only 
produced by hepatocyte, and in hepatic cirrhosis patients, 
functional hepatocyte that secretes TPO is decreased, 
which leads to decreases in TPO secretion[14-16], even if the 
spleen does not destroy PLT, in circulating blood PLT may 
be decreased still. Some scholars who think[17] in cirrhosis 
patients, the immune system is dysfunctional and various 
hemocyte autoantibodies are produced, among which, 
PAIgG is the most close to hypersplenism. PAIgG is a kind 
of platelet autoantibody combined with the glycoprotein 
on the surface of the platelet membrane, mainly produced 
by the spleen, and significantly increased in patients with 
thrombocytopenic purpura and hepatic cirrhosis. PAIgG 
combined platelets are easily captured and phagocytized 
by antibody mediated macrophage when flowing through 
the spleen. Furthermore, PAIgG can also combine with 
megakaryocytes and their precursors to destroy the 
megakaryocytes, the precursors and to inhibit their 
differentiation and platelet formation. 
  Clinically, genuine single type WBC, RBC and PLT 
decreases only account for 9.4%, 16.9% and 10% respectively, 
and in most cases, 2 or more kinds of blood cell decrease[18]. 
Regardless of multiple or single type blood cell decreases, 
the decreased blood cells significantly increased after 
splenectomy (P<0.01), among which, PLT were most 
susceptible to increase, even starting half an hour after 
the surgery, peaking in 2 weeks[19], and then gradually 
decreasing and stabilizing at a normal level[20]; next was 
WBC and RBC. Mastuura et al[21]suggested that the excessive 
postoperative PLT count was also a life-threatening 
factor, so the condition of the patient should be closely 
monitored[22,23]. It has been proven in recent years that 
autologous stem cell transplantation has good therapeutic 
effects on peripheral blood cell decrease in cirrhotic portal 
hypertension[24]. 
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